Non-small cell lung cancer is the most common type of lung cancer, lung cancer patients in nearly 80% of all the types. Advanced non-small cell lung cancer patients are usually through surgery, radiotherapy and chemotherapy in combination with acceptance of the treatment plan.
In recent years, the market for different types of shark cartilage extract products, known as the "selection-substitute anticancer agents", provided for by blocking tumor blood vessel formation of nutrients to exert anti-cancer effect. But before that for different types of shark cartilage products for medical research have not been found to extend survival for patients with cancer. The University of Texas at Anderson Cancer Center's team to 384 advanced non-small cell lung cancer patients in a clinical study for objects, once again proved that shark cartilage extract does not have anticancer effects.
Course of study, in accepting conventional radiotherapy and chemotherapy treatment, patients are divided into two groups, namely supplementary shark cartilage extract and placebo. Results show that the two groups of average survival in patients with and without obvious differences, supplementary shark cartilage extract of a group of average survival 14.4 months, and the placebo group average survival 15.6 months.
The research team felt that the clinical trial results show that in conventional radiotherapy and chemotherapy of supplementary shark cartilage extract, and does not extend the survival of patients with lung cancer. Researchers said that this result may cause cancer patients disappointed, but also instructions for some of the typically so-called "strict anti-cancer substances" science is necessary to avoid cancer patients believe these so-called "replacement therapy," blindly attempt.
No comments:
Post a Comment